CAS 184475-35-2 Cancer Cure Drug Raw Material Powder Gefitinib 99% Purity

Basic Information
Place of Origin: China
Brand Name: Senwayer Brand
Certification: ISO, 9001, USP
Model Number: 184475-35-2
Minimum Order Quantity: 10grams
Price: Discount is possible if your order is big enough
Packaging Details: 10g, 20g, 50g , 100g, 500g. 1kg, 10kg
Delivery Time: within 2 working days
Payment Terms: T/T in advance, Money Gram, Western Union, Bank Transfer.
Supply Ability: 1000kg/month
Detail Information
CAS: 184475-35-2 Apparence: Almost White Crystalline Powder
Purity: 99% Other Name: N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
MF: C22H24ClFN4O3 MW: 446.9
EINECS: 643-034-7 Usage: Antitumor
High Light:

anti cancer drugs


antineoplastic drugs

Product Description

Medical Effective Gefitinib Iressa Cancer Treating Raw Material Powder 184475-35-2
Quick detail

Product Name: Gefitinib
Synonyms: IRESSA;GEFITINIB;AKOS 91371;n-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine;N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine;ZD 1839;4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-;Gefitinib(TINIBS)
CAS: 184475-35-2
MF: C22H24ClFN4O3
MW: 446.9
Product Categories: Active Pharmaceutical Ingredients;Gefitinib;Molecular Targeted Antineoplastic;Intermediates & Fine Chemicals;Pharmaceuticals;Pharmaceutical intermediate;APIs;IRESSA;Anti-cancer&immunity;API;Inhibitors

Recommended Antineoplastic products

LapatinibCAS : 231277-92-2Cisplatin15663-27-1
Dasatinib302962-49-8Vincristine sulfate2068-78-2
Gefitinib184475-35-2Nimustine hydrochloride55661-38-6
Sunitinib Malate341031-54-7Gemcitabine95058-81-4
Erlotinib hydrochloride183319-69-9 107868-30-4Paclitaxel33069-62-4
Doxorubicin hydrochloride25316-40-9Docetaxel114977-28-5
Mitomycin C50-07-7(Podophyllotoxin)nsc24818518-28-5

Recommended Antineoplastic products:


Gefitinib​ ​Description :

Gefitinib (ZD1839) (INN, , trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers. Gefitinib is an EGFR inhibitor, like erlotinib, which interrupts signaling through the epidermal growth factor receptor (EGFR) in target cells. Therefore, it is only effective in cancers with mutated and overactive EGFR. However, meta-analyses have not shown any improvement in overall survival, that is, it does not extend life.
Gefitinib is used to treat non-small cell lung cancer that has spread to other parts of the body in people with certain types of tumors. Gefitinib is in a class of medications called kinase inhibitors. It works by blocking the action of a certain naturally occurring substance that may be needed to help cancer cells multiply.
How you have Gefitinib : 

Gefitinib comes as a tablet to take by mouth. It is usually taken with or without food once a day. Take gefitinib at around the same time every day. Follow the directions on your prescription label carefully, and ask your doctor or pharmacist to explain any part you do not understand. Take gefitinib exactly as directed. Do not take more or less of it or take it more often than prescribed by your doctor.
If you are unable to swallow the tablets, you may dissolve them in water. Place one tablet in 4 to 8 ounces (120 to 240 mL) of plain, noncarbonated drinking water. Stir with a spoon for about 15 minutes until the tablet is dissolved. Drink the mixture right away. Rinse the glass with another 4 to 8 ounces (120 to 240 mL) of water and drink the rinse water right away to be sure that you swallow all of the medication.
Your doctor may delay or permanently stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with gefitinib.
What special precautions should I follow?

Before taking gefitinib,

  • tell your doctor and pharmacist if you are allergic to gefitinib, any other medications, or any of the ingredients in gefitinib tablets. Ask your pharmacist for a list of the ingredients.
  • tell your doctor and pharmacist what prescription and nonprescription medications, vitamins, and nutritional supplements you are taking or plan to take. Be sure to mention any of the following: anticoagulants ('blood thinners') such as warfarin (Coumadin, Jantoven); antifungals such as itraconazole (Onmel, Sporanox) and ketoconazole (Nizoral); metoprolol (Lopressor, Toprol XL, in Dutoprol); phenytoin (Dilantin, Phenytek); and tricyclic antidepressants such as imipramine (Tofranil) and amitriptyline. Many other medications may interact with gefitinib, so be sure to tell your doctor about all the medications you are taking, even those that do not appear on this list. Your doctor may need to change the doses of your medications or monitor you carefully for side effects.
  • if you are taking an antacid or an H2 blocker medication for indigestion, heartburn, or ulcers such as cimetidine (Tagamet), famotidine (Pepcid), nizatidine (Axid), or ranitidine (Zantac), take them at least 6 hours before or 6 hours after taking gefitinib.
  • if you are taking a proton pump inhibitor medication for indigestion, heartburn, or ulcers such as esomeprazole (Nexium), lansoprazole (Prevacid), omeprazole (Prilosec), pantoprazole (Protonix), or rabeprazole (AcipHex), take it at least 12 hours before or at least 12 hours after taking gefitinib.
  • tell your doctor if you have or have ever had pulmonary fibrosis (scarring of the lungs) or other lung or breathing problems, eye or vision problems, or liver disease.
  • tell your doctor if you are pregnant or plan to become pregnant. Gefitinib may cause infertility (difficulty becoming pregnant) in females. However, you should use birth control to prevent pregnancy during your treatment with gefitinib and for at least 2 weeks after you stop taking the medication. If you become pregnant while taking gefitinib, call your doctor. Gefitinib may harm the fetus and increase the risk of pregnancy loss.
  • tell your doctor if you are breastfeeding. You should not breast-feed while you are taking gefitinib.

Gefitinib COA





Slight white to white crystalline powder

White crystalline powder

Identification IR(1)

Conforms to the refence

Conforms to the refence

Melting Point






Assay (HPLC)



Individual Purity (HPLC )




Conform with company standard

CAS 184475-35-2 Cancer Cure Drug Raw Material Powder Gefitinib 99% Purity 0 

Contact Details
Abby Xiang

Phone Number : +8617764031156

WhatsApp : +8617764031156